We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · December 05, 2020

Avelumab Maintenance After First-line Induction Chemotherapy vs Continuation of Chemotherapy in Gastric Cancer

Journal of Clinical Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100
J. Clin. Oncol 2020 Nov 16;[EPub Ahead of Print], M Moehler, M Dvorkin, N Boku, M Özgüroğlu, MH Ryu, AS Muntean, S Lonardi, M Nechaeva, AC Bragagnoli, HS Coşkun, A Cubillo Gracian, T Takano, R Wong, H Safran, GM Vaccaro, ZA Wainberg, MR Silver, H Xiong, J Hong, J Taieb, YJ Bang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading